US Expansion INBRAIN is actively expanding into the United States with a Boston location and plans for a West Coast presence, alongside a Mayo Clinic know-how collaboration. Potential sales angles include market-entry support, regulatory strategy, and hospital network integration to accelerate adoption of graphene-based neural therapies.

AI Cloud Alliances Strategic partnerships with Microsoft and Kyndryl indicate a strong emphasis on AI-driven BCI therapies and enterprise IT. Potential sales angles include offering Azure-based AI/ML platforms, secure data infrastructure, and systems integration for clinical data, imaging, and edge-connected neural devices.

Regulatory and Funding FDA Breakthrough Designation signals regulatory momentum and faster path to approval, complemented by modest funding and growing revenue. Potential sales angles include regulatory affairs and quality systems consulting, funding advisory, and co-investment opportunities or collaboration on trials.

Therapeutic Focus Focus on graphene-based neural technologies for central and peripheral applications with BCI-Tx capabilities, aiming at neurology therapies. Potential sales angles include partnerships with hospitals and research centers for pilots, device integration, clinical data capture, and reimbursement strategy support.

Ecosystem Partnerships Active collaboration with tech and services players, including Kyndryl and Microsoft, suggests a platform approach and need for system integrators and data infrastructure. Potential sales angles include SI partnerships, enterprise IT integration, secure data workflows, and cross-sell opportunities into healthcare IT ecosystems.